Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Breast Neoplasms 189Neoplasm Metastasis 19Neoplasms 9Ovarian Neoplasms 8Breast Diseases 6Triple Negative Breast Neoplasms 4Prostatic Neoplasms 4Pancreatic Neoplasms 4Endometrial Neoplasms 4Advanced Breast Cancer 4Neoplasms by Site 3Lung Neoplasms 3Hereditary Sensory and Autonomic Neuropathies 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Recurrence 2Rectal Neoplasms 2Neoplasm, Residual 2Multiple Myeloma 2Melanoma 2Inflammation 2Hematologic Neoplasms 2Fallopian Tube Neoplasms 2Estrogen Receptor-positive Breast Cancer 2

Interventions

palbociclib 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Endometrioid × palbociclib × Breast × Clear all
NCT04498520 2021-05-18

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer

University of California, San Francisco

Phase 1 Withdrawn
BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Carcinoma, Endometrioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡